Patient Dies In Pfizer's Long -term Extension Trial Of Hemophilia Drug

Pfizer Inc. (PFE) has announced that a participant in the long-term extension trial evaluating Marstacimab in people living with hemophilia A or B with or without inhibitors has passed away following serious adverse events of cerebellar infarction and subsequent cerebral hemorrhage.The individual completed the active treatment phase of the parent study, dubbed B7841005, in 2022 and subsequently enrolled in the long-term extension study in 2023.B7841005 was a phase 3 trial that included adolescents and adul ...